BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev. 2014;28:1-7. [PMID: 24395243 DOI: 10.1101/gad.228452.113] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Guo L, Zhang S, Wang J, Lin X, Gao F. PRSS1 mutation: a possible pathomechanism of pancreatic carcinogenesis and pancreatic cancer. Mol Med 2019;25:44. [PMID: 31521106 DOI: 10.1186/s10020-019-0111-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther 2015;15:1223-31. [PMID: 26402249 DOI: 10.1586/14737140.2015.1086271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
3 Na K, Hernandez-Prera JC, Lim JY, Woo HY, Yoon SO. Characterization of novel genetic alterations in salivary gland secretory carcinoma. Mod Pathol. 2020;33:541-550. [PMID: 31822803 DOI: 10.1038/s41379-019-0427-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Benzel J, Fendrich V. Familial Pancreatic Cancer. Oncol Res Treat. 2018;41:611-618. [PMID: 30269130 DOI: 10.1159/000493473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
5 Lankadasari MB, Mukhopadhyay P, Mohammed S, Harikumar KB. TAMing pancreatic cancer: combat with a double edged sword. Mol Cancer 2019;18:48. [PMID: 30925924 DOI: 10.1186/s12943-019-0966-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
6 Boursi B, Finkelman B, Giantonio BJ, Haynes K, Rustgi AK, Rhim AD, Mamtani R, Yang YX. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology. 2017;152:840-850.e3. [PMID: 27923728 DOI: 10.1053/j.gastro.2016.11.046] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 13.4] [Reference Citation Analysis]
7 Das KK, Early D. Pancreatic cancer screening. Curr Treat Options Gastroenterol. 2017;15:562-575. [PMID: 28879469 DOI: 10.1007/s11938-017-0149-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. J Cell Biochem 2015;116:2824-39. [PMID: 25981734 DOI: 10.1002/jcb.25229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
9 Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, Tam M, Pisanic TR 2nd, Iacobuzio-Donahue CA, Hruban RH, He J, Wang TH, Wood LD, Sharma A, Ahuja N. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11:59. [PMID: 30953539 DOI: 10.1186/s13148-019-0650-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
10 Li M, Chen Q, Ma T, Yu X. Targeting reactive nitrogen species suppresses hereditary pancreatic cancer. Proc Natl Acad Sci U S A 2017;114:7106-11. [PMID: 28630313 DOI: 10.1073/pnas.1702156114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Tan M, Brusgaard K, Gerdes AM, Mortensen MB, Detlefsen S, Schaffalitzky de Muckadell OB, Joergensen MT. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study. Scand J Gastroenterol 2021;56:965-71. [PMID: 34165379 DOI: 10.1080/00365521.2021.1937697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, Unger B, Prokop JW, Heidel JR, Wang XX, Ukaegbu CI, Jennings BC, Paulo JA, Gableske S, Fierke CA, Getz G, Sunyaev SR, Wade Harper J, Cichowski K, Kimmelman AC, Houvras Y, Syngal S, Williams C, Goessling W. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet 2019;51:1308-14. [PMID: 31406347 DOI: 10.1038/s41588-019-0475-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
13 Pittman ME, Brosens LA, Wood LD. Genetic Syndromes with Pancreatic Manifestations. Surg Pathol Clin. 2016;9:705-715. [PMID: 27926368 DOI: 10.1016/j.path.2016.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
14 Eguchi H, Kobayashi S, Gotoh K, Noda T, Doki Y. Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes. Ann Gastroenterol Surg 2020;4:229-33. [PMID: 32490337 DOI: 10.1002/ags3.12326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 De Unamuno B, García-Casado Z, Bañuls J, Requena C, Lopez-Guerrero JA, Nagore E. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer. Melanoma Res 2018;28:246-9. [PMID: 29543703 DOI: 10.1097/CMR.0000000000000442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
16 Rajurkar M, Dang K, Fernandez-Barrena MG, Liu X, Fernandez-Zapico ME, Lewis BC, Mao J. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. Cancer Res 2017;77:320-9. [PMID: 28069799 DOI: 10.1158/0008-5472.CAN-15-1684] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
17 Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol 2016;22:7275-88. [PMID: 27621574 DOI: 10.3748/wjg.v22.i32.7275] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
18 Gall TM, Wasan H, Jiao LR. Pancreatic cancer: current understanding of molecular and genetic aetiologies. Postgrad Med J 2015;91:594-600. [PMID: 26124188 DOI: 10.1136/postgradmedj-2014-133161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC. Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. Pancreas 2018;47:924-36. [PMID: 30113427 DOI: 10.1097/MPA.0000000000001136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
20 Zhang X, Ma N, Yao W, Li S, Ren Z. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell Int 2019;19:356. [PMID: 31889908 DOI: 10.1186/s12935-019-1077-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
21 Ohmoto A, Yachida S, Morizane C. Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Int J Mol Sci. 2019;20. [PMID: 30699894 DOI: 10.3390/ijms20030561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
22 Moreira L, Castells A. Surveillance of patients with hereditary gastrointestinal cancer syndromes. Best Pract Res Clin Gastroenterol 2016;30:923-35. [PMID: 27938787 DOI: 10.1016/j.bpg.2016.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Kumar S, Metz DC, Kaplan DE, Goldberg DS. The association of Helicobacter pylori with pancreatic cancer. GastroHep 2020;2:157-64. [PMID: 33692655 DOI: 10.1002/ygh2.398] [Reference Citation Analysis]
24 Sarnecka AK, Zagozda M, Durlik M. An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma. J Cancer 2016;7:2045-51. [PMID: 27877219 DOI: 10.7150/jca.15323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
25 Vaz AP, Ponnusamy MP, Seshacharyulu P, Batra SK. A concise review on the current understanding of pancreatic cancer stem cells. J Cancer Stem Cell Res 2014;2:e1004. [PMID: 26451384 DOI: 10.14343/jcscr.2014.2e1004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
26 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
27 Frank TS, Sun X, Zhang Y, Yang J, Fisher WE, Gingras MC, Li M. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett 2015;363:1-6. [PMID: 25890222 DOI: 10.1016/j.canlet.2015.04.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
28 Udgata S, Takenaka N, Bamlet WR, Oberg AL, Yee SS, Carpenter EL, Herman D, Kim J, Petersen GM, Zaret KS. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. Cancer Prev Res (Phila) 2021;14:223-32. [PMID: 33067248 DOI: 10.1158/1940-6207.CAPR-20-0403] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Abe K, Ueki A, Urakawa Y, Kitago M, Yoshihama T, Nanki Y, Kitagawa Y, Aoki D, Kosaki K, Hirasawa A. Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report. Hered Cancer Clin Pract 2021;19:5. [PMID: 33413558 DOI: 10.1186/s13053-020-00160-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9. [PMID: 28701476 DOI: 10.1126/scitranslmed.aah5583] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 33.7] [Reference Citation Analysis]
31 Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, Montalto G, Cervello M, Steelman L, Abrams SL, McCubrey JA. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv Biol Regul 2015;59:65-81. [PMID: 26257206 DOI: 10.1016/j.jbior.2015.06.003] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 14.2] [Reference Citation Analysis]
32 De Paolis E, Urbani A, Salvatore L, Foca L, Tortora G, Minucci A, Concolino P. A Novel ATM Pathogenic Variant in an Italian Woman with Gallbladder Cancer. Genes (Basel) 2021;12:313. [PMID: 33671809 DOI: 10.3390/genes12020313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shih CY, Chattopadhyay A, Wu CH, Tien YW, Lu TP. Transcript annotation tool (TransAT): an R package for retrieving annotations for transcript-specific genetic variants. BMC Bioinformatics 2021;22:350. [PMID: 34182919 DOI: 10.1186/s12859-021-04243-z] [Reference Citation Analysis]
34 Kumar S, Saumoy M, Oh A, Schneider Y, Brand RE, Chak A, Ginsberg GG, Kochman ML, Canto MI, Goggins MG, Hur C, Kastrinos F, Katona BW, Rustgi AK. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas 2021;50:807-14. [PMID: 34149034 DOI: 10.1097/MPA.0000000000001835] [Reference Citation Analysis]
35 Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. Pancreatic cancer actionable genes in precision medicine and personalized surgery. Surgeon 2017;15:24-9. [PMID: 27374183 DOI: 10.1016/j.surge.2016.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Osterman M, Kathawa D, Liu D, Guo H, Zhang C, Li M, Yu X, Li F. Elevated DNA damage response in pancreatic cancer. Histochem Cell Biol. 2014;142:713-720. [PMID: 25002126 DOI: 10.1007/s00418-014-1245-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73-85. [PMID: 26830752 DOI: 10.1016/s0140-6736(16)00141-0] [Cited by in Crossref: 995] [Cited by in F6Publishing: 579] [Article Influence: 199.0] [Reference Citation Analysis]
38 Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV, Banerjee S. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Curr Genomics 2018;19:444-63. [PMID: 30258276 DOI: 10.2174/1389202919666180221160753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
39 Sun S, Osterman MD, Li M. Tissue specificity of DNA damage response and tumorigenesis. Cancer Biol Med 2019;16:396-414. [PMID: 31565474 DOI: 10.20892/j.issn.2095-3941.2019.0097] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
40 Martinez-Useros J, Garcia-Foncillas J. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int 2016;2016:1869304. [PMID: 28078281 DOI: 10.1155/2016/1869304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
41 Reddy N, Malipatil B, Kumar S. A rare case of familial multiple subcutaneous lipomatosis with novel PALB2 mutation and increased predilection to cancers. Hematol Oncol Stem Cell Ther 2016;9:154-6. [PMID: 26845227 DOI: 10.1016/j.hemonc.2016.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
42 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 12.7] [Reference Citation Analysis]
43 Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, Meshinchi S, Pugh TJ, Shern JF, Lipson D. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res 2017;77:509-19. [PMID: 28069802 DOI: 10.1158/0008-5472.CAN-16-1106] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
44 Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014;8:739-747. [PMID: 24882381 DOI: 10.1586/17474124.2014.925799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
45 Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci 2017;18:E779. [PMID: 28383487 DOI: 10.3390/ijms18040779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
46 Huo Y, Selenica P, Mahdi AH, Pareja F, Kyker-Snowman K, Chen Y, Kumar R, Da Cruz Paula A, Basili T, Brown DN, Pei X, Riaz N, Tan Y, Huang YX, Li T, Barnard NJ, Reis-Filho JS, Weigelt B, Xia B. Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. NPJ Breast Cancer 2021;7:45. [PMID: 33893322 DOI: 10.1038/s41523-021-00253-5] [Reference Citation Analysis]
47 Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer 2015;15:166-80. [PMID: 25709118 DOI: 10.1038/nrc3891] [Cited by in Crossref: 287] [Cited by in F6Publishing: 250] [Article Influence: 47.8] [Reference Citation Analysis]
48 Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacol Res 2020;155:104740. [PMID: 32135247 DOI: 10.1016/j.phrs.2020.104740] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
49 Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Itakura A, Takeda S, Hasegawa K, Inoue S. Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing. Int J Mol Sci 2019;20:E4330. [PMID: 31487856 DOI: 10.3390/ijms20184330] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]